Engineered dCas12f1-SAM enables robust transcriptional activation and gain-of-function screening in primary human cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42086608.
- Also identified by DOI 10.1038/s41467-026-72833-7.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite considerable powers, the application of CRISPR activation (CRISPRa) screens in primary human cells remains a formidable challenge. Here, we develop dCas12f1-SAM, a compact SAM-based transcriptional activation platform, that outperforms existing systems in both immortalized cell lines and primary human T cells and hematopoietic stem/progenitor cells (HSPCs). Using dCas12f1-SAM, we perform a pooled CRISPRa screen targeting 1559 human transcription factors (TFs) in primary human T cells and identify multiple positive regulators of IL-2 expression. We further implement a single-cell CRISPRa screen via our miCROP-seq construct, resolving how these genetic perturbations reshape T cell activation dynamics and drive functionally distinct cellular states. Among the top-ranking genes, we spotlight KLF12 and LHX5, whose overexpression significantly improves antigen-specific responses of chimeric antigen receptor T (CAR-T) cells. Collectively, these findings establish dCas12f1-SAM as a robust transcriptional activation tool, highlighting its potential to advance applications in cellular engineering and immunotherapy.